Pharma BD Deal Intelligence

GSK plc / Chimagen Biosciences

2026 · Asset Purchase · $750M · Pending

GSK plc agreed to acquire full global rights to a preclinical trispecific T cell-engager programme from privately held Chimagen Biosciences for a total potential value of up to $750 million, comprising an undisclosed upfront fee plus success-based development and commercial milestones. The candidate binds T cells while simultaneously targeting two validated tumour-associated antigens rather than a single tumour target, and GSK plans to develop and commercialise it in multiple myeloma with Phase I entry expected in 2027. This is GSK's second transaction with Chimagen, following a 2024 agreement worth up to $850 million covering a separate T cell engager.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  GSK plc deals